rac 4-Hydroxydebrisoquine Hemisulfate
rac 4-Hydroxydebrisoquine Hemisulfate结构式
|
常用名 | rac 4-Hydroxydebrisoquine Hemisulfate | 英文名 | rac 4-Hydroxydebrisoquine Hemisulfate |
|---|---|---|---|---|
| CAS号 | 62580-84-1 | 分子量 | 289.30800 | |
| 密度 | N/A | 沸点 | N/A | |
| 分子式 | C10H15N3O5S | 熔点 | 262-265ºC | |
| MSDS | 中文版 美版 | 闪点 | N/A | |
| 符号 |
GHS07 |
信号词 | Warning |
|
Microsomal formation of nitric oxide and cyanamides from non-physiological N-hydroxyguanidines: N-hydroxydebrisoquine as a model substrate.
Biochem. Pharmacol. 58(3) , 439-45, (1999) The microsomal oxidative transformation of a non-physiological N-hydroxyguanidine was demonstrated for the first time for N-hydroxydebrisoquine as a model substrate (Clement et al., Biochem Pharmacol 46: 2249-2267, 1993). The objective of the present work was... |
|
|
Halofantrine and chloroquine inhibit CYP2D6 activity in healthy Zambians.
Br. J. Clin. Pharmacol. 45(3) , 315-7, (1998) To determine the effect of therapeutic loading doses of halofantrine and chloroquine on CYP2D6 activity in healthy black Zambians.Twenty healthy black male Zambians were phenotyped for CYP2D6 activity by measuring the debrisoquine/4-hydroxydebrisoquine ratio ... |
|
|
Determination of debrisoquine and 4-hydroxydebrisoquine by high-performance liquid chromatography: application to the evaluation of CYP2D6 genotype and debrisoquine metabolic ratio relationship.
Clin. Chem. Lab Med. 43(3) , 275-9, (2005) The drug-metabolizing cytochrome P450 (CYP) enzyme CYP2D6 is involved in the metabolism of several clinically important drugs. So far more than 50 different CYP2D6 allelic variants have been described, and thus there is an increased need for routine high-perf... |
|
|
Enantioselectivity in the steady-state pharmacokinetics of metoprolol in hypertensive patients.
Chirality 11(7) , 591-7, (1999) In the present study we investigated the enantioselectivity in the pharmacokinetics of metoprolol administered in a multiple-dose regimen as the racemate. The study was conducted on 10 patients of both sexes with mild to severe essential hypertension, aged 28... |
|
|
Debrisoquine hydroxylation in Parkinson's disease.
Acta Neurol. Scand 86(2) , 159-64, (1992) Debrisoquine (DBQ) metabolism was studied in 80 Parkinson's disease (PD) patients, 26 of whom had young onset Parkinson's disease (YOPD), and in 143 controls. There was no significant difference between the proportion of poor metabolisers of DBQ among YOPD pa... |
|
|
Determination of debrisoquine and 4-hydroxydebrisoquine in urine by high-performance liquid chromatography with fluorescence detection after solid-phase extraction.
J. Pharm. Biomed. Anal. 11(8) , 745-9, (1993) A simple, selective and sensitive method has been developed to determine debrisoquine and 4-hydroxydebrisoquine in human urine. Separation of the analytes was obtained using a mobile phase of 0.1 M sodium dihydrogen phosphate-acetonitrile (87:13, v/v) and a m... |
|
|
Influence of chronic renal failure on stereoselective metoprolol metabolism in hypertensive patients.
J. Clin. Pharmacol. 45(12) , 1422-33, (2005) The influence of chronic renal failure on the stereoselective metabolism of rac-metoprolol was investigated in 15 hypertensive patients, 7 of them with chronic renal failure and 8 with normal renal function. They were treated with rac-metoprolol (200 mg) for ... |
|
|
CYP2D6 phenotypes among Malays in Malaysia.
J. Clin. Pharm. Ther. 25(5) , 379-83, (2000) Although they originated from China, Malays have undergone a lot of intermarriages. A study suggested that CYP2D6 poor metabolism (PM) phenotype was more common in Malays compared to Chinese. CYP2D6 is highly polymorphic and is involved in the metabolism of m... |
|
|
Changes in debrisoquine hydroxylation capacity following liver surgery.
Hum. Exp. Toxicol. 13(8) , 537-41, (1994) Liver transplantation or the surgical construction of portacaval shunts may radically alter an individual's debrisoquine hydroxylation capacity. Good clinical management should encompass a full awareness of such changing needs and problems in patients who und... |
|
|
Determination of oxidation phenotype by measurement of propafenone urinary metabolic ratios.
Hum. Exp. Toxicol. 12(2) , 161-3, (1993)
|